| Abstract PO3-29-04: Patient selection for high RSK2 expression is key for achieving improved PFS in metastatic breast cancer in the PMD-026 Phase 1/1b study S Dunn, J Wang, H Han, R Wesolowski, A Patnaik, S Bahadur, ... Cancer Research 84 (9_Supplement), PO3-29-04-PO3-29-04, 2024 | | 2024 |
| RSK1 is an exploitable dependency in myeloid malignancies T Kong, A Laranjeira, LY Yu, JS Fowles, DAC Fisher, S Ng, W Yang, F He, ... Blood 142 (Supplement 1), 46-46, 2023 | 1 | 2023 |
| Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion C Kosnopfel, S Wendlinger, H Niessner, J Siewert, T Sinnberg, ... Journal of Experimental & Clinical Cancer Research 42 (1), 175, 2023 | 7 | 2023 |
| Abstract P4-01-16: High levels of RSK2 in breast cancer patients is associated with longer PFS in patients treated with PMD-026, a first in class RSK inhibitor JS Wang, M Beeram, P Chalasani, L Mina, RA Shatsky, S Hurvitz, ... Cancer Research 83 (5_Supplement), P4-01-16-P4-01-16, 2023 | | 2023 |
| Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multiforme and medulloblastoma DM Brown, J Bacha, S Dunn US Patent App. 17/689,467, 2022 | | 2022 |
| PMD-026, a first in class oral RSK inhibitor, demonstrates activity against hormone receptor positive breast cancer with acquired CDK4/6 inhibitor resistance A Jayanthan, L Yue, M Huynh, G Los, SE Dunn Cancer Research 82 (12_Supplement), 5378-5378, 2022 | | 2022 |
| Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multiforme and medulloblastoma DM Brown, J Bacha, S Dunn US Patent App. 17/583,141, 2022 | | 2022 |
| Crystalline forms of an rsk inhibitor R Winnike, E McPherson, E Flahive, J LOUGHREY US Patent App. 17/429,603, 2022 | | 2022 |
| Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multiforme and medulloblastoma DM Brown, J Bacha, S Dunn US Patent 11,234,955, 2022 | | 2022 |
| Histologic correlates of molecular group 4 pediatric medulloblastoma: a retrospective Canadian review J Triscott, S Yip, D Johnston, J Michaud, SR Rassekh, J Hukin, S Dunn, ... Pediatric and Developmental Pathology 24 (4), 309-317, 2021 | 4 | 2021 |
| N-(1-((heterocyclyl) methyl)-1h-pyrazol-4-yl)-6-oxo-6, 7, 8, 9-tetrahydropyrido [3', 2': 4, 5] pyrrolo [l, 2-a] pyrazine-2-carboxamide derivatives as p90 ribosomal s6 kinase … SE Dunn, A JAYANTHAN, JR Nagireddy, S Annedi, JH Van Drie, ... | 1 | 2021 |
| PMD-026, a first in class oral RSK inhibitor, demonstrates synergy when combined with standard of care in breast cancer tumor models A Jayanthan, M Huynh, J Lee, G Los, L Yue, MR Pambid, NT Ueno, ... Proceedings of the American Association for Cancer Research Annual Meeting …, 2021 | 3 | 2021 |
| Targeting B-RAF and checkpoint inhibitor resistant melanoma with RSK inhibitor PMD-026 in pre-clinical models JW Ramos, S Si, T Fujii, B Haun, WS Yang, A Jayanthan, SE Dunn Cancer Research 81 (13_Supplement), 1218-1218, 2021 | 1 | 2021 |
| First-in-human phase 1/1b expansion of PMD-026, an oral RSK inhibitor, in patients with metastatic triple-negative breast cancer. M Beeram, P Chalasani, JS Wang, LA Mina, RA Shatsky, MS Trivedi, ... Journal of Clinical Oncology 39 (15_suppl), e13043-e13043, 2021 | 6 | 2021 |
| 6-Oxo-N-(1-(benzyl)-1H-pyrazol-4-YL)-6, 7, 8, 9-tetrahydropyrido [3', 2': 4, 5] pyrrolo [1, 2-A] pyrazin-2-carboxamid-derivater som P90 ribosomal S6 kinase-(RSK-) hæmmere til … SE Dunn, A JAYANTHAN, JR Nagireddy, S Annedi, DJH Van, ... | | 2021 |
| Abstract PS11-33: A first-in-human Phase 1/1b multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026, a first-in-class oral RSK inhibitor … M Beeram, JS Wang, P Chalasani, L Mina, A Patnaik, MR Pambid, ... Cancer Research 81 (4_Supplement), PS11-33-PS11-33, 2021 | | 2021 |
| A first-in-human Phase 1/1b multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026, a first-in-class oral RSK inhibitor, in metastatic … M Beeram, JS Wang, P Chalasani, L Mina, A Patnaik, MR Pambid, ... CANCER RESEARCH 81 (4), 2021 | 1 | 2021 |
| First-in-human expansion study of oral PMD-026 in metastatic triple negative breast cancer patients M Beeram, JS Wang, LA Mina, P Chalasani, RA Shatsky, R Wesolowski, ... PS11-33, SABCS, 2021 | 1 | 2021 |
| Dr Sandi Dunn illuminates emerging key treatment approaches and companion diagnostics for triple negative breast cancer S Dunn Expert Opinion on Investigational Drugs 29 (12), 1309-1312, 2020 | | 2020 |
| The dawn of targeted therapies for triple negative breast cancer (TNBC): A snapshot of investigational drugs in phase I and II trials M Huynh, MR Pambid, A Jayanthan, A Dorr, G Los, SE Dunn Expert opinion on investigational drugs 29 (11), 1199-1208, 2020 | 20 | 2020 |
